Rare diseases
Investigational molecules
Locations
Study on Empagliflozin to Prevent Heart Damage in Cancer Patients Receiving Anthracycline Chemotherapy
PolandStudy on the Effects of Empagliflozin for Patients with Cardiogenic Shock
FranceStudy on the Effects of Empagliflozin, Pioglitazone, and Semaglutide for Patients with Type 2 Diabetes
DenmarkStudy on the Effectiveness and Safety of Tocilizumab and Drug Combination for Patients with Metastatic Breast Cancer
FranceEfficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin
GermanyEffect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery
FranceStudy of Empagliflozin, Losartan Potassium and Hydrochlorothiazide to Prevent Kidney Stones in Patients with Paraffin Oil Induced Granulomatous Disease
DenmarkStudy of Empagliflozin to Improve Heart Function in Adults with Pulmonary Arterial Hypertension
GermanyStudy on Preventing Acute Kidney Injury After Heart Surgery Using Empagliflozin in Patients Undergoing Elective Cardiac Surgery
SpainStudy on Acetazolamide with Empagliflozin and Dapagliflozin for Patients with Acute Heart Failure and Fluid Retention
BelgiumStudy on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes
BelgiumStudy on Empagliflozin for Patients with Non-Alcoholic Steatohepatitis (NASH)
CzechiaTell us about your condition – we search every trial in Europe and connect you with the right site.
